Pappanaicken R Kumar, PhD
Department of Leukemia, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Leukemia - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Assistant Professor, Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1994 | The University of Madras, Chennai, US, Ph.D. in Biochemistry |
| 1990 | The University of Madras, Chennai, IN, M.Phil in Biochemistry |
Postgraduate Training
| 1996-2000 | Post-Doctoral Fellowship, Microbiology and Immunology, The University of North Texas and Health Science Center, Fort Worth, Texas |
Experience & Service
Academic Appointments
Assistant Professor, Department of Lymphoma/Myeloma - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2022
Associate Professor-I (Research), Department of Biochemistry, The University of California Davis School of Medicine, Sacramento, 2011 - 2012
Assistant Professor-IV (Research), The University of California Davis school of Medicine, Sacramento, 2009 - 2011
Assistant Professor-III (Research), The University of California Davis school of Medicine, Sacramento, 2007 - 2009
Assistant Professor-II (Research), Department of Internal Medicine, The University of California Davis school of Medicine, Sacramento, 2005 - 2007
Assistant Professor-I (Research), Department of Hematology/Oncology, The University of California Davis School of Medicine, Sacramento, 2003 - 2005
Assistant Professor, Department of Microbiology and Immunology, The University of North Texas Health Science Center, Fort Worth, 2003 - 2008
Assistant Professor, Department of Microbiology and Immunology, The University of North Texas Health Science Center, Fort Worth, TX, 2000 - 2002
Other Appointments/Responsibilities
Assistant Professor, Medical Mycology Research Center, The UT MD Anderson Cancer Center, Houston, TX, 2018 - Present
Research Scientist, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2016
Research Investigator, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2014
Institutional Committee Activities
committee member, Onboarding/Exit Clearance Committee (OECC), 2018 - Present
Honors & Awards
| 2016 | 2016-ISCT-Technologist Award, International Society for Cellular Therapy |
| 2014 | Best abstract travel award, International Cancer Biology Conference |
| 2013 | Outstanding Poster Award in “Infections in Cancer Symposium, Department of Infectious diseases |
| 2007 - 2009 | Exploration-Hypothesis Development Award, Chronic Myelogenous Leukemia Research Program |
| 2002 | Junior Faculty Travel Award, American Association of Immunologist |
| 1991 - 1994 | Senior Research Fellowship, National Council of Scientific and Industrial Research, India |
| 1989 - 1991 | Junior Research Fellowship, National Council of Scientific and Industrial Research, India |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Kumaresan PR. A novel lentiviral vector-based approach to generate chimeric antigen receptor T cells targeting Aspergillus fumigatus. mBio 15(4):03413-23, 2024. e-Pub 2024. PMID: 38415653.
- Machado MP, Dos Santos MH, Guimarães JG, de Campos GY, Oliveira Brito PKM, Ferreira CMG, Rezende CP, Frota NF, Soares SG, Kumaresan PR, Lourenzoni MR, da Silva TA. GXMR-CAR containing distinct GXM-specific single-chain variable fragment (scFv) mediated the cell activation against Cryptococcus spp. And had difference in the strength of tonic signaling. Bioengineered 14(1):2281059, 2023. e-Pub 2023. PMID: 37978838.
- Dos Santos MH, Machado MP, Kumaresan PR, da Silva TA. Modification of hinge/transmembrane and signal transduction domains improves the expression and signaling threshold of GXMR-CAR specific to Cryptococcus spp. Cells 11(21), 2022. e-Pub 2022. PMID: 36359781.
- Dos Santos MH, Machado MP, Kumaresan PR, da Silva TA. Titan Cells and Yeast Forms of Cryptococcus neoformans and Cryptococcus gattii Are Recognized by GXMR-CAR. Microorganisms 9(9), 2021. e-Pub 2021. PMID: 34576780.
- da Silva TA, Hauser PJ, Bandey I, Laskowski T, Wang Q, Najjar AM, Kumaresan PR. Glucuronoxylomannan in the Cryptococcus species capsule as a target for Chimeric Antigen Receptor T-cell therapy. Cytotherapy 23(2):119-130, 2021. e-Pub 2021. PMID: 33303326.
- Wurster S, Kumaresan PR, Albert ND, Hauser PJ, Lewis RE, Kontoyiannis DP. Live Monitoring and Analysis of Fungal Growth, Viability, and Mycelial Morphology Using the IncuCyte NeuroTrack Processing Module. mBio 10(3), 2019. e-Pub 2019. PMID: 31138745.
- Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, Jena B, Dawson MJ, Kumaresan PR, Su S, Maiti S, Dai J, Moriarity B, Forget MA, Senyukov V, Orozco A, Liu T, McCarty J, Jackson RN, Moyes JS, Rondon G, Qazilbash M, Ciurea S, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Kantarjian H, Keating M, Wierda W, Do KA, Largaespada DA, Lee DA, Hackett PB, Champlin RE, Cooper LJ. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest 126(9):3363-76, 2016. e-Pub 2016. PMID: 27482888.
- Kumaresan P, Figliola M, Moyes JS, Huls MH, Tewari P, Shpall EJ, Champlin R, Cooper LJ. Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System. J Vis Exp(104), 2015. e-Pub 2015. PMID: 26484782.
- Krishnamurthy J, Rabinovich BA, Mi T, Switzer KC, Olivares S, Maiti SN, Plummer JB, Singh H, Kumaresan PR, Huls HM, Wang-Johanning F, Cooper LJ. Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on Melanoma. Clin Cancer Res 21(14):3241-51, 2015. e-Pub 2015. PMID: 25829402.
- Guo W, Liu R, Bhardwaj G, Yang JC, Changou C, Ma AH, Mazloom A, Chintapalli S, Xiao K, Xiao W, Kumaresan P, Sanchez E, Yeh CT, Evans CP, Patterson R, Lam KS, Kung HJ. Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor. Cell Death Dis 5:e1409, 2014. e-Pub 2014. PMID: 25188519.
- Kumaresan PR, Manuri PR, Albert ND, Maiti S, Singh H, Mi T, Roszik J, Rabinovich B, Olivares S, Krishnamurthy J, Zhang L, Najjar AM, Huls MH, Lee DA, Champlin RE, Kontoyiannis DP, Cooper LJ. Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proc Natl Acad Sci U S A 111(29):10660-5, 2014. e-Pub 2014. PMID: 25002471.
- Kumaresan PR, Devaraj S, Huang W, Lau EY, Liu R, Lam KS, Jialal I. Synthesis and characterization of a novel inhibitor of C-reactive protein-mediated proinflammatory effects. Metab Syndr Relat Disord 11(3):177-84, 2013. e-Pub 2013. PMID: 23445482.
- Devaraj S, Kumaresan PR, Jialal I. C-reactive protein induces release of both endothelial microparticles and circulating endothelial cells in vitro and in vivo: further evidence of endothelial dysfunction. Clin Chem 57(12):1757-61, 2011. e-Pub 2011. PMID: 21980169.
- Kumaresan PR, Wang Y, Saunders M, Maeda Y, Liu R, Wang X, Lam KS. Rapid discovery of death ligands with one-bead-two-compound combinatorial library methods. ACS Comb Sci 13(3):259-64, 2011. e-Pub 2011. PMID: 21302937.
- Xiao W, Wang Y, Lau EY, Luo J, Yao N, Shi C, Meza L, Tseng H, Maeda Y, Kumaresan P, Liu R, Lightstone FC, Takada Y, Lam KS. The use of one-bead one-compound combinatorial library technology to discover high-affinity αvβ3 integrin and cancer targeting arginine-glycine-aspartic acid ligands with a built-in handle. Mol Cancer Ther 9(10):2714-23, 2010. e-Pub 2010. PMID: 20858725.
- Kumaresan PR, Luo J, Lam KS. On-demand cleavable linkers for radioimmunotherapy. Methods Mol Biol 539:191-211, 2009. e-Pub 2009. PMID: 19377973.
- Natarajan A, Kumaresan PR, Denardo SJ, Denardo GL, Mirick G, Lam KS. Development of TNKase-specific cleavable peptide-linked radioimmunoconjugates for radioimmunotherapy. Bioorg Med Chem Lett 18(17):4802-5, 2008. e-Pub 2008. PMID: 18701282.
- Luo J, Zhang H, Xiao W, Kumaresan PR, Shi C, Pan CX, Aina OH, Lam KS. Rainbow beads: a color coding method to facilitate high-throughput screening and optimization of one-bead one-compound combinatorial libraries. J Comb Chem 10(4):599-604, 2008. e-Pub 2008. PMID: 18558750.
- Kumaresan PR, Luo J, Song A, Marik J, Lam KS. Evaluation of ketone-oxime method for developing therapeutic on-demand cleavable immunoconjugates. Bioconjug Chem 19(6):1313-8, 2008. e-Pub 2008. PMID: 18494516.
- Lee JK, Mathew SO, Vaidya SV, Kumaresan PR, Mathew PA. CS1 (CRACC, CD319) induces proliferation and autocrine cytokine expression on human B lymphocytes. J Immunol 179(7):4672-8, 2007. e-Pub 2007. PMID: 17878365.
- Kumaresan PR, Natarajan A, Song A, Wang X, Liu R, DeNardo G, DeNardo S, Lam KS. Development of tissue plasminogen activator specific "on demand cleavable" (odc) linkers for radioimmunotherapy by screening one-bead-one-compound combinatorial peptide libraries. Bioconjug Chem 18(1):175-82, 2007. e-Pub 2007. PMID: 17226971.
- Mathew SO, Kumaresan PR, Lee JK, Huynh VT, Mathew PA. Mutational analysis of the human 2B4 (CD244)/CD48 interaction: Lys68 and Glu70 in the V domain of 2B4 are critical for CD48 binding and functional activation of NK cells. J Immunol 175(2):1005-13, 2005. e-Pub 2005. PMID: 16002700.
- Devaraj S, Kumaresan PR, Jialal I. Effect of C-reactive protein on chemokine expression in human aortic endothelial cells. J Mol Cell Cardiol 36(3):405-10, 2004. e-Pub 2004. PMID: 15010279.
- Mathew PA, Chuang SS, Vaidya SV, Kumaresan PR, Boles KS, Pham HT. The LLT1 receptor induces IFN-gamma production by human natural killer cells. Mol Immunol 40(16):1157-63, 2004. e-Pub 2004. PMID: 15104121.
- Kumaresan PR, Lai WC, Chuang SS, Bennett M, Mathew PA. CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function. Mol Immunol 39(1-2):1-8, 2002. e-Pub 2002. PMID: 12213321.
- Chuang SS, Kumaresan PR, Mathew PA. 2B4 (CD244)-mediated activation of cytotoxicity and IFN-gamma release in human NK cells involves distinct pathways. J Immunol 167(11):6210-6, 2001. e-Pub 2001. PMID: 11714782.
- Chuang SS, Pham HT, Kumaresan PR, Mathew PA. A prominent role for activator protein-1 in the transcription of the human 2B4 (CD244) gene in NK cells. J Immunol 166(10):6188-95, 2001. e-Pub 2001. PMID: 11342640.
- Kumaresan PR, Mathew PA. Structure of the human natural killer cell receptor 2B4 gene and identification of a novel alternative transcript. Immunogenetics 51(11):987-92, 2000. e-Pub 2000. PMID: 11003394.
- Kumaresan PR, Stepp SE, Verrett PC, Chuang SS, Boles KS, Lai WC, Ryan JC, Bennett M, Kumar V, Mathew PA. Molecular characterization of the rat NK cell receptor 2B4. Mol Immunol 37(12-13):735-44, 2000. e-Pub 2000. PMID: 11275258.
- Kumaresan PR, Huynh VT, Mathew PA. Polymorphism in the 2B4 gene of inbred mouse strains. Immunogenetics 51(8-9):758-61, 2000. e-Pub 2000. PMID: 10941850.
- Boles KS, Barten R, Kumaresan PR, Trowsdale J, Mathew PA. Cloning of a new lectin-like receptor expressed on human NK cells. Immunogenetics 50(1-2):1-7, 1999. e-Pub 1999. PMID: 10541800.
Invited Articles
- Kumaresan P, Figliola M, Tewari P, Moyes J, Huls H, Cooper L. Automating the manufacture of clinically appealing designer T cells. Treatment Strategies-Blood and Bone marrow Transplantation 1(1):55-60, 2014. e-Pub 2014.
Other Articles
- Kumaresan PR, da Silva TA, Kontoyiannis DP Methods of Controlling Invasive Fungal Infections Using CD8+ T Cells. Front Immunol 8:1939, 2017. PMID: 29358941.
- Liu R, Shih TC, Deng X, Anwar L, Ahadi S, Kumaresan P, Lam KS Design, synthesis, and application of OB2C combinatorial peptide and peptidomimetic libraries. Methods Mol Biol 1248:3-22, 2015. PMID: 25616322.
- Kumaresan P Chemical antibodies for cancer immunotherapy. DOD-CDMRL-Annual report, 2008.
- Nawarathna D, Kumaresan P, Zhang Y, Ferguson B, S-H O, Lam, KS, Soh HT Continuous magnetophoretic enrichment of rare tumor cells. Micro DAS annual Proceedings, 2007.
- Kumaresan PR, Lam KS Screening chemical microarrays: methods and applications. Mol Biosyst 2(5):259-70, 2006. PMID: 16880944.
Abstracts
- Kumaresan P, Nathaniel A, Singh H, Olivares S, Maiti SN, Mi T, Huls H, Champlin RE, Kontoyiannis DP, Cooper LJ. Bioengineered Dectin-1 CAR+ T cells to control invasive fungal infection. Cancer Immunology Research 4(1, Supplement):A193, 2016. e-Pub 2016.
- Kumaresan P, Nathaniel A, Singh H, Krishnamoorthi J, Olivares S, MMaiti S, Huls M, TiejuanMi, EChamplin R, PKontoyiannis D, JNCooper AL. Innovative Dual CAR-T Cells to Target B-Cell Leukemia and Opportunistic Fungal Agents. Molecular Therapy 23(Supplement1):S211, 2015. e-Pub 2015.
- Kumaresan P, Nathaniel A, Singh H, Krishnamoorthi J, Olivares S, MMaiti S, Huls M, TiejuanMi, EChamplin R, PKontoyiannis D, JNCooper AL. Dual-Specificity CAR plus T Cells to Target B-Cell Malignancies and Opportunistic Fungal Infection. Biology of Blood and marrow Transplantation 20(2, Supplement):S123, 2014. e-Pub 2014.
- Tewari P, Kumaresan P, Figliola M, Huls H, Longin K, Ruhnke K, Champlin R, and Cooper LJ. Automated Production of Clinical-Grade CMV-Specific T Cells to Implement Immunotherapy at the Bedside. Biology of Blood and marrow Transplantation 20(2 Supplement):S136-S137, 2014. e-Pub 2014.
- Kumaresan P, Manuri PR, Albert N, Rabinovich B, Olivares S, Maiti SN, Huls H, Lee DA, Kontoyiannis D, Cooper LJ. Bioengineering cytotoxic T cells to target opportunistic fungal infection. J Immunother Cancer 1(Suppl):P4, 2013. e-Pub 2013.
- Kumaresan P, Dhamne C, Maiti S, Krishnamoorthy J, Thokala R, Huls H, Richard C, Lee D, Tran D, Cooper L. Regulatory T Cells Suitable for Clinical Use Can Be Propagated on Artificial Antigen Presenting Cells. Molecular Therapy 21(1, Supplement):S166, 2013. e-Pub 2013.
- Ishwarlal J, Kumaresan P, and Lam K. A Novel small molecule Inhibitor to C-Reactive Protein attenuates CRP's Pro-Inflammatory Effects In-Vivo. FASEB Journal 27(1, Supplement):379.12, 2013. e-Pub 2013.
- Wang Y, Maeda Y, Qin S, Lam K, Liu R, Kumaresan P. A novel small molecule drug (LWKS) for pancreatic cancer therapy. Cancer Research 71(8, Supplement):2593, 2011. e-Pub 2011.
- Moses E, Maeda Y, Kumaresan P. Chemical antibodies for cancer immunotherapy. Cancer Research 70(8, Supplement):5623, 2010. e-Pub 2010.
- Wang Y, Maeda Y, Kaur I, Lam K, and Kumaresan P. Discovery of novel small molecule drugs against pancreatic cancer. Cancer Research 69(Supplement 9):1559, 2009. e-Pub 2009.
- Kumaresan P, Ahir V, Liu R, Lam K. Identification of cancer specific high affinity targeting ligands by screening One-bead-one-compound and small molecule. Molecular Cancer Therapeutics 6(12):3408S-Part2, 2007. e-Pub 2007.
- Kumaresan P, Ahir V, Liu R, Lam K. Identification of cancer specific high affinity targeting ligands by screening One-bead-one-compound and small molecule. Molecular Cancer Therapeutics 6(12):3408S-Part2, 2007. e-Pub 2007.
- Kumaresan PR, Lai W, Chuang S, Bennett M, Mathew P. Identification of the ligand for CS-1, a novel member of the CD2 subset of immunoglobulin superfamily. FASEB Journal 39(1-2), 2002. e-Pub 2002.
- Kumaresan PR, Lai W, Chuang S, Bennett M, Mathew P. Identification of the ligand for CS-1, a novel member of the CD2 subset of immunoglobulin superfamily. FASEB Journal 39(1-2), 2002. e-Pub 2002.
Book Chapters
- Kumaresan, PR, daSilva T, Kontoyiannis, DP. Methods of Controlling Invasive Fungal Infections Using CD8+ T Cells. In: 1.Immunity to human fungal pathogens: Mechanism of host recognition, protection, pathology and fungal interference. Frontiers in Microbiology and Frontiers in Immunology, 425-438, 2019.
- Kumaresan PR, Lam K. Screening chemical microarrays: Methods and Applications. In: Exploiting chemical diversity for drug discovery. RSC publishing, 291-307, 2006.
- Lam KS, Liu R, Marik J, Kumaresan PR. From one bead one compound combinatorial libraries to chemical microarrays. In: Micro/Nano Genomics and Proteomics in biomembranes and Biomeical Nanotechnology Encyclopedia. Springer, 283-304, 2006.
Selected Presentations & Talks
National Presentations
- 2024. CAR T cell to treat invasive fungal infections. Conference. American association of Immunology. Chicago, Illinois, US.
- 2024. CAR T cell to treat invasive fungal infections. Conference. American association of Immunology. Chicago, Illinois, US.
- 2023. Chimeric Antigen Receptor (CAR) T cells to control invasive Aspergillus infections. Conference. Chimeric Antigen Receptor (CAR) T cells to control invasive Aspergillus infections. Galveston, TX, US.
- 2019. Bioengineered CAR T cells to control Cryptococci species infection. Conference. Bioengineered CAR T cells to control Cryptococci species infection. Madison, WI, US.
- 2017. Aspergillus hyphae length analysis using the IncuCyte neurotrack module. Conference. Department of Pediatrics-Research. Galveston, TX, US.
- 2015. Bi-specific CAR T cells to treat B-cell leukemia and invasive fungal infections. Conference. Department of Pediatrics-Research. New Orleans, LA, US.
- 2015. Harnessing immunity to fungi in the clinic. Conference. Department of pediatrics-Research. Galveston, TX, US.
International Presentations
- 2024. Bio-engineered cell therapy to treat invasive fungal infections. Conference. Internation Society for Cell Therapy. Vancouver, CA.
- 2019. CAR T cell therapy to control cryptocccus species infection. Conference. Video Presentation. Barcelona, ES.
- 2019. Design and Development of CAR T cells for clinical use. Conference. Apollo Cancer Conclave. Chennai, IN.
- 2016. Unassisted production of clinical grade viral specific T cells: Bringing production to the bedside. Conference. International Society for Cellular Therapy. Singapore, SG.
- 2014. Innovative dual CAR T cells to target B-cell leukemia and control opportunistic fungal infections. Conference. Cancercon-2014. Chennai, IN.
Formal Peers
- 2023. "CAR T cell therapy” in general and connect to invasive fungal infections. Invited. "CAR T cell therapy” in general and connect to invasive fungal infections. Fort Worth, TX, US.
- 2008. The use of one-bead-two-compound peptide and lipopeptide libraries for identification of cell signaling and proapoptotic ligands fto target cancer cells. Invited. The use of one-bead-two-compound peptide and lipopeptide libraries for identification of cell signaling and proapoptotic ligands fto target cancer cells. Sacramento, CA, US.
- 2008. Identification of pro-apoptotic ligands by screening one-bead-two compounds combinatorial library. Invited. Identification of pro-apoptotic ligands by screening one-bead-two compounds combinatorial library. Chennai, Tamil Nadu, IN.
Grant & Contract Support
| Date: | 2024 - 2026 |
| Title: | Bio-engineered cell therapy to treat candidiasis |
| Funding Source: | NIH/NIAID |
| Role: | PI |
| ID: | R21 |
| Date: | 2022 - 2023 |
| Title: | Personalizing CAR T-cell therapy; Collaboration ID: ECLIPSE:BCell-0131 |
| Funding Source: | M.D. Anderson Moon Shots |
| Role: | Research Scientist |
| Date: | 2022 - 2025 |
| Title: | Bi-cistronic CAR+ γζ T-cells to target AML and control invasive fungal infections |
| Funding Source: | Leukemia SPORE grant |
| Role: | PI |
| ID: | Interrnal |
| Date: | 2021 - 2023 |
| Title: | CAR T cells to treat invasive fungal infections |
| Funding Source: | NIH/NIAID |
| Role: | PI |
| ID: | R33-diversity supplemental grant |
| Date: | 2021 - 2023 |
| Title: | Bi-cistronic CAR+ γζ T-cells to target AML and control invasive fungal infections |
| Funding Source: | IRG |
| Role: | PI |
| Date: | 2019 - 2019 |
| Title: | Bi-specific CAR NK cells to control leukemia and invasive fungal infections |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | AWD00001631 |
| Date: | 2018 - 2021 |
| Title: | Redirected CAR T cells therapy to cure invasive fungal infections |
| Funding Source: | NIH/NIAID |
| Role: | Multi-Principal Investigator |
| ID: | R33-AI127381-03 |
| Date: | 2016 - 2018 |
| Title: | Redirected CAR T cells therapy to cure invasive fungal infections |
| Funding Source: | NIH/NIAID |
| Role: | Multi-Principal Investigator |
| ID: | R21 AI127381-01 |
| Date: | 2013 - 2015 |
| Title: | Development of CAR-T cells for pancreatic cancer therapy |
| Funding Source: | Sheikh Ahmed Bin Zayed Al Nahyan Center for Pancreatic Cancer Research |
| Role: | Co-I |
| Date: | 2011 - 2011 |
| Title: | Bispecific immunoconjugates to target breast cancer malignancies |
| Funding Source: | UC Davis Clinical and Translational Science Center Innovative Award |
| Role: | PI |
| Date: | 2009 - 2011 |
| Title: | C-reactive protein, Diabetes and Atherothrombosis |
| Funding Source: | NIH/NHLBI |
| Role: | Collaborator |
| ID: | NIH-RO1-ARRA |
| Date: | 2007 - 2010 |
| Title: | Identification of Pancreatic Cancer Specific High Affinity Targeting Ligands |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | RO3-CA129786-01 |
| Date: | 2007 - 2009 |
| Title: | Novel Targeted Immunotherapy for CML Blast cells |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | PI |
| ID: | CM064046 |
Patient Reviews
CV information above last modified April 22, 2025